TABLE 1.
Patients’ baseline characteristics
| Variables | 2DE | ELISA | ||||
|---|---|---|---|---|---|---|
| BAV n=5 |
TAV n=5 |
p-value | BAV n=6 |
TAV n=9 |
p-value | |
| Age* | 49.2 ± 10.2 | 63.2 ± 8.6 | 0.1 | 48.5 ± 9.3 | 57.7 ± 7.9 | 0.1 |
| Gender (female:male) | 0:5 | 0:5 | 1 | 0:6 | 3:6 | 0.1 |
| Max. aortic diameter (mm)* | 59 ± 3.5 | 59.4 ± 2.8 | 0.8 | 58.3 ± 3.6 | 56.2 ± 4.4 | 0.4 |
| Aortic valve insufficiency | 1 (20%) | 3 (60%) | 0.2 | 2 (33%) | 5 (56%) | 0.4 |
| Arterial Hypertension | 1 (20%) | 3 (60%) | 0.2 | 3 (50%) | 3 (33%) | 0.5 |
| Diabetes mellitus | 0 | 0 | - | 0 | 0 | - |
| Non-stenotic coronary artery disease | 2 (40%) | 2 (40%) | 1 | 2 (33%) | 2 (22%) | 0.6 |
| Dyslipidemia | 0 | 2 (40%) | 0.1 | 2 (33%) | 3 (33%) | 1 |
| Smoking history | 1 (20%) | 3 (60%) | 0.2 | 1 (17%) | 3 (33%) | 0.5 |
| Preoperative dyspnea (=NYHA II) | 2 (40%) | 3 (60%) | 0.5 | 2 (33%) | 6 (67%) | 0.2 |
| LVEF (%)* | 64.8 ± 4.8 | 56.8 ± 12.3 | 0.3 | 63.2 ± 5.8 | 58.5 ± 11.3 | 0.3 |
| Preoperative medication | ||||||
| Betablocker | 2 (40%) | 1 (20%) | 0.5 | 2 (33%) | 3 (33%) | 1 |
| ACE inhibitor/AT II antagonist | 1 (20%) | 3 (60%) | 0.2 | 2 (33%) | 6 (67%) | 0.2 |
| Aortic valve replacement | 4 (80%) | 4 (80%) | 1 | 5 (83%) | 6 (67%) | 0.5 |
| Ascending aorta replacement | 3 (60%) | 2 (40%) | 0.5 | 4 (67%) | 6 (67%) | 1 |
Abbreviations: BAV=Bicuspid Aortic Valve; TAV=Tricuspid Aortic Valve; NYHA=New York Heart Association Classification,
*
in mean ± SD